Cytokine gene polymorphism [tumor necrosis factor-alpha (–308), IL-10 (–1082), IL-6 (–174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities (original) (raw)

2016, Blood Coagulation & Fibrinolysis

To evaluate the association between development, progression, and response to therapy among patients with immune thrombocytopenia (ITP) and different cytokine gene polymorphisms known to be related to autoimmunity [tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, IL-6, IL-17, IL-1Ra]. A total of 50 pediatric patients with ITP (20 newly diagnosed, 30 chronic) and 50 healthy controls were investigated via PCR-restriction fragment length polymorphism analysis for cytokine gene polymorphism. Compared with controls, all patients showed a higher frequency of IL-6S174 CC [P U 0.0001, odds ratio (OR) U 7.048, 95% confidence interval (CI) U 2.18-22.7], higher GA genotype of TNF-a (S308) (P U 0.001, OR U 6.469, 95% CI U 2.0-20.9), higher CC genotype of IL-17F (P U 0.0001, OR U 55.545, 95% CI U 14.4-213.2), higher GG of IL-10S1082 (P U 0.029, OR U 3.6, 95% CI U 1.08-12.18), and A1A2 genotype of IL-1Ra VNTR (P U 0.039, OR U 2.374, 95% CI U 1.03-5.4). IL-10 GA and IL-1Ra A1A1 genotypes were higher among chronic patients (P U 0.042, P U 0.001 respectively) compared with newly diagnosed ones. Best platelet response to steroid treatment was found among GC genotype of IL-6 (-174) and GG genotype of IL-10 (-1082) in all patients with ITP. This suggests that previously mentioned cytokine gene polymorphisms possibly contribute to the susceptibility of acquisition of childhood ITP. Furthermore, GA genotype of IL-10 and A1A1 genotype of IL-1Ra polymorphisms are associated with increased risk of chronic ITP. IL-6 (-174) and IL-10 (-1082) genes might play a role in the effectiveness of steroid therapy among patients with ITP.